Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Astellas Pharma

Founders Erik Karrer

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 11
Average round size
info
The average size of a deal this fund participated in
$15M
Portfolio companies 11
Rounds per year 0.58
Lead investments 5
Exits 4
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Genetics
Summary

Astellas Pharma is the famous Corporate Investor, which was founded in 2005. The main department of described Corporate Investor is located in the Tokyo. The fund was located in Asia if to be more exact in Japan.

The fund has specific favorite in a number of founders of portfolio startups. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Life Science. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight FibroGen, CoMentis, Catalia Health.

The fund was created by Erik Karrer.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Astellas Pharma, startups are often financed by Khosla Ventures, Wellington Partners, Silicon Valley Growth Syndicate. The meaningful sponsors for the fund in investment in the same round are The House Fund, Shibuya Kogyo, Shanda Group. In the next rounds fund is usually obtained by Tony Ling, SMBC Venture Capital, SBI Investment.

The top amount of exits for fund were in 2017. Considering the real fund results, this Corporate Investor is 23 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. Opposing the other organizations, this Astellas Pharma works on 0 percentage points less the average amount of lead investments. The fund is constantly included in less than 2 investment rounds annually.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Astellas Pharma:
Typical Co-investors
Astellas Pharma is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Astellas Pharma:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Adani Capital Central, Central Region, Singapore
Ajayi Solutions -
Bondi Pacific Pty Ltd Australia, New South Wales, Sydney
GMT Communications Partners England, London, United Kingdom
GRO Capital Copenhagen, Denmark, Hovedstaden
Jaszac Investments -
Lisa Dean Moseley Foundation -
Mela Ventures Bengaluru, India, Karnataka
OSS Capital, L.P. California, San Francisco, United States
SevenBridge Financial Group Harrisburg, Pennsylvania, United States
Shanghai Yousu Investment Management China, Shanghai
Shell Energy North America Houston, Texas, United States
SHiP China, Guangdong, Shenzhen
Stratos Ventures Finland, Helsinki, Southern Finland
Sustainable Ocean Alliance -
Tigerlabs New Jersey, Princeton, United States
VectoIQ LLC New York, New York, United States
VOYAGERS Health-Tech Fund -
Zall Group China, Hubei, Wuhan

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Iota Biosciences

Biotechnology
$15M27 Dec 2018 Berkeley, California, United States

Heartseed

Health Care
$7M30 Jul 2018 Chiyoda

Mitobridge

Biotechnology
Life Science
Therapeutics
$5M04 Oct 2013 Cambridge, Massachusetts, United States

Telsar Pharma

Biotechnology
Health Care
Medical Device
$14M24 Apr 2012 New Jersey, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Astellas Pharma?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 11
Average round size 15M
Rounds per year 0.58
Peak activity year 2018
Lead investments 5
Exits 4
Group Appearance index 0.55

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Iota Biosciences

Biotechnology
$15M27 Dec 2018 Berkeley, California, United States

Heartseed

Health Care
$7M30 Jul 2018 Chiyoda

Mitobridge

Biotechnology
Life Science
Therapeutics
$5M04 Oct 2013 Cambridge, Massachusetts, United States

Telsar Pharma

Biotechnology
Health Care
Medical Device
$14M24 Apr 2012 New Jersey, United States
Crunchbase icon

Content report

The following text will be sent to our editors: